



Akebia Therapeutics  
Investor Relations Department  
245 First Street  
Suite 1100  
Cambridge, MA 02142  
United States


Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

**NASDAQ: AKBA**

Last Trade:	14.24
Trade Time:	4:15 PM ET May 24, 2017
Change:	0.29 <span style="color: green;">↑</span> (2.079%)
Day Range	13.70 - 14.26
52-Week Range	7.00 - 15.88
Volume	435,423

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Stock Performance



### Press Releases [\[ View all \]](#)

May 24, 2017

[Akebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents](#)

May 15, 2017

[Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval](#)

May 9, 2017

[Akebia Announces First Quarter 2017 Financial Results](#)

May 4, 2017

[Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Apr 25, 2017

[Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories](#)

### Financials [\[ View all \]](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

May 1, 2017

[Proxy Statement \(DEF 14A\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)

Nov 9, 2016

[Quarterly Report \(10-Q\)](#)

Aug 8, 2016

[Quarterly Report \(10-Q\)](#)